Financial Review: Petros Pharmaceuticals (NASDAQ:PTPI) & Cuprina Holdings (Cayman) (NASDAQ:CUPR)
Head to Head Contrast: Petros Pharmaceuticals (NASDAQ:PTPI) vs. Statera Biopharma (NASDAQ:STAB)
Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position
Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets
Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer
Petros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI Platform
Petros Pharmaceuticals Developing First-in-Industry SaaS Platform Utilizing AI and Electronic Health Records Intended to Facilitate Rx-OTC Switches
Petros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification Reforms
Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications
Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study
Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants
Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules
Petros Pharmaceuticals Featured in “New Era of Healthcare, AI, Data and Consumer Empowerment”
Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
Petros Pharmaceuticals' STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider
Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider
Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch
Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology Provider
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology Provider
Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)
Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA
Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA Label
Petros Pharmaceuticals to Present at the LD Micro Main Event XVI
Petros Pharmaceuticals Provides Letter to Shareholders
Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Petros Pharmaceuticals Announces Capital Raise of $15 Million
Top Penny Stocks Chart Patterns to Use to Profit
Penny Stock Due Diligence: Top Research Techniques
Buying Energy Penny Stocks? 3 Methods to Use
Petros Pharmaceuticals to Present at the Planet MicroCap Showcase 2022
3 Hot Penny Stocks to Add to Your Small-Caps Watch List This Week
Best Penny Stocks, How To Buy & Strategies for Beginners
What Are Penny Stocks? What You Need to Know and 3 to Watch
Petros Pharmaceuticals to Present at the Q1 Investor Summit Conference
Best Penny Stocks To Buy This Week? 4 Short Squeeze Stocks To Watch
3 Reddit Penny Stocks For Your Watch List In January 2022
Short Squeeze Stocks: ISIG, RELI and 3 Others Experts Think Are Ready to Pop
Short Squeeze Stocks: ISIG, AVCT and 5 Others Experts Think Are Ready to Pop
4 Penny Stocks To Buy For Under $5 With High Short Interest
Top Penny Stocks to Buy Now? Check These 3 Out For the New Year